文献速递急性肾损伤慢性肾脏病

8周达拉他韦联合减量索磷布韦治疗晚期肾功能不全急性丙肝

Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

本研究评估8周达拉他韦联合半剂量索磷布韦方案治疗eGFR<30 mL/min的急性丙肝患者。27例患者完成治疗,治疗4周及8周末HCV RNA均检测不到,停药12周后持续病毒学应答率按意向治疗为92.6%(25/27),按方案为96.2%(25/26)。该方案有效,可作为资源有限地区昂贵肾脏安全口服抗HCV药物的替代选择。

要点

  • 8周达拉他韦联合半剂量索磷布韦治疗eGFR<30 mL/min急性丙肝有效。
  • 持续病毒学应答率意向治疗92.6%,按方案96.2%。
  • 该方案或可替代昂贵肾脏安全口服抗HCV药物。

核心结论

  • 8周达拉他韦联合半剂量索磷布韦对eGFR<30 mL/min的急性丙肝患者有效,持续病毒学应答率高。

研究设计与样本

  • 回顾性队列研究,检索临床记录纳入31例急性丙肝且eGFR<30 mL/min的初治无肝硬化成人,其中27例接受8周达拉他韦60 mg联合索磷布韦200 mg每日一次治疗。

主要发现

  • 27例患者中位年龄36岁(范围18-74),男性20例(74%),全部完成8周治疗。
  • 治疗4周及治疗结束时所有27例HCV RNA均检测不到。
  • 停药12周后,25例HCV RNA阴性,1例阳性,1例死亡(无关原因);持续病毒学应答率意向治疗25/27(92.6%),按方案25/26(96.2%)。

关键数值与推荐

  • 急性丙肝定义为HCV病毒血症且血清丙氨酸氨基转移酶活性升高≥10倍。
  • eGFR<30 mL/min患者使用索磷布韦200 mg(半剂量)联合达拉他韦60 mg每日一次,疗程8周,不考虑HCV基因型。

临床怎么用

  • 对于eGFR<30 mL/min的急性丙肝患者,可考虑8周达拉他韦联合半剂量索磷布韦方案,尤其在资源有限地区作为昂贵肾脏安全药物的替代。

局限性

  • 回顾性研究,样本量较小(27例治疗),非随机对照,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sofosbuvir is not recommended in persons with estimated glomerular filtration rate (eGFR) <30 mL/min. We report the results of treatment with an off-label 8-week regimen of daclatasvir and half-dose sofosbuvir in patients with acute infection with hepatitis C virus ( HCV) and eGFR <30 mL/min. METHODS: Clinic records were searched to identify treatment-naïve, noncirrhotic adults with acute hepatitis C (HCV viremia and a ≥10-fold elevation of serum alanine aminotransferase activity) and eGFR <30 mL/min, who had been treated with a sofosbuvir-based regimen. Treatment response was assessed using serum HCV RNA testing at 4 weeks of treatment, end of the 8-week treatment and 12 weeks after stopping treatment. RESULTS: Of the 31 patients with acute hepatitis C, 27 [median age (range): 36 (18-74) years; 20 (74%) male] were started on treatment with 200 mg sofosbuvir and 60 mg daclatasvir daily for 8 weeks, irrespective of HCV genotype. All the 27 completed the planned 8-week treatment. One patient died 10 weeks after completing the treatment of an unrelated cause. All the 27 patients had undetectable HCV RNA after 4 weeks of and at the end of treatment. At 12 weeks after completion of treatment, only one tested HCV RNA positive and 25 were negative, with sustained virological response rate of 25/27 (92.6%) and 25/26 (96.2%) on intention-to-treat and per-protocol basis, respectively. CONCLUSION: Eight-week course of daclatasvir and half-dose sofosbuvir is effective for acute hepatitis C in patients with eGFR <30 mL/min and could be a useful alternative to costly, kidney-safe anti-HCV oral drugs in resource-constrained settings.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Goel A, Bhadauria DS, Kaul A, et al. Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir. Nephrol Dial Transplant. 2021. PMID: 33097949. doi:10.1093/ndt/gfaa187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。